DexCom, Inc.
DXCM Large CapHealthcare · Medical Devices
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
DexCom, Inc. en bref
DexCom, Inc. (DXCM) is currently trading at 63,24 € with a market capitalization of 24,4 Md €. The trailing P/E ratio stands at 31.1x, with a forward P/E of 23.51x. The 52-week range spans from 47,22 € to 78,52 €; the current price is 19.5% below the yearly high. Year-over-year revenue growth stands at +15.0%. The net profit margin stands at 19.31%.
💰 Dividende
DexCom, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
24 analystes évaluent DexCom, Inc. (DXCM) au consensus : Achat Fort. L'objectif de cours moyen est de 74,36 €, soit un potentiel de +17.58% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 56,72 € à 97,74 €.
DexCom, Inc. : la thèse d'investissement en détail
DexCom, Inc. (DXCM) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 15% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 92.2% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 61.5%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Valorisation en contexte
The PEG ratio at 1.36 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
À surveiller
- The forward P/E of 23.51x is meaningfully below the trailing 31.1x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Rentabilité élevée des capitaux propres (35.62% ROE)
- Marge brute élevée de 61.5% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- Bilan solide avec faible endettement (D/E 46.83)
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (5.19%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy DexCom, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news